GreeneSAndersonAWilckenMJehleDVarneyS.
Regional differences in systemic toxicity following Texas coral snake (Micrurus tener) envenomations. Wilderness Environ Med.
2025 Mar 19:10806032251327124. doi: https://doi.org/10.1177/10806032251327124
2.
StephenSMohantyCRRadhakrishnanRVIssacAJacobJKrishnanN, et al.Clinico-epidemiological profile, trends, and health-related outcomes of snakebite victims: a one-year prospective study from eastern India. Wilderness Environ Med.
2024;
35(
2):
155–
165.
VelagapudiMENavarroJJHillAEDarracqMAThorntonSL.
Epidemiology and characteristics of coral snake bites reported to the National Poison Data System (2006‒2022). J Am Coll Emerg Physicians Open.
2024;
5(
5):
e13296.
5.
TednesMSlesingerTL.
Evaluation and Treatment of Snake Envenomations[Updated 2024 Sep 10]. In: StatPearls[Internet]. StatPearls Publishing;2025. https://www.ncbi.nlm.nih.gov/books/NBK553151/
6.
GreeneSRuhaAMCamplemanSBrentJWaxP; ToxIC Snakebite Study Group.
Epidemiology, clinical features, and management of Texas coral snake (Micrurus tener) envenomations reported to the North American Snakebite Registry. J Med Toxicol.
2021;
17(
1):
51–
56.
7.
CarterRWGerardoCJSamuelSPKumarSKotehalSDMukherjeePP, et al.; BRAVO Study Group.
The BRAVO clinical study protocol: oral varespladib for inhibition of secretory phospholipase A2 in the treatment of snakebite envenoming. Toxins (Basel).
2022;
15(
1):
22.
8.
MohantyCRBarikAKRadhakrishnanRVBeheraSJayaramanG.
Phospholipase A2 inhibitors: potential treatment options for future snakebite envenomation!. Am J Emerg Med.
2024;
86:
168–
169.
9.
NorrisRLPfalzgrafRRLaingG.
Death following coral snake bite in the United States—first documented case (with ELISA confirmation of envenomation) in over 40 years. Toxicon.
2009;
53(6):
693–
697.
